3 results match your criteria: "Center for Integrative Infectious Diseases (CIID)[Affiliation]"

A breath of fresh air: targeted non-viral in vivo gene correction in the mammalian lung.

Signal Transduct Target Ther

October 2024

Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Medical Faculty, University of Heidelberg, BioQuant, Center for Integrative Infectious Diseases (CIID), 69120, Heidelberg, Germany.

View Article and Find Full Text PDF

Goody two plasmids: An optimized transient transfection system for AAV vector production.

Mol Ther Methods Clin Dev

September 2023

Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Medical Faculty, University of Heidelberg, BioQuant, Center for Integrative Infectious Diseases (CIID), 69120 Heidelberg, Germany.

View Article and Find Full Text PDF

Progress in Bioengineering of Myotropic Adeno-Associated Viral Gene Therapy Vectors.

Hum Gene Ther

May 2023

Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Medical Faculty, University of Heidelberg, BioQuant, Center for Integrative Infectious Diseases (CIID), Heidelberg, Germany.

Article Synopsis
  • The study focuses on enhancing gene therapy delivery to muscle tissues using recombinant adeno-associated viruses (AAVs), which are engineered to carry therapeutic agents more effectively and safely.
  • Various techniques are employed to create muscle-targeting AAV capsids by modifying existing wild-type sequences, leading to novel capsid libraries that can be tested in different animal models.
  • Recent advancements have produced specialized AAV variants named AAVMYO or MyoAAV, known for their high effectiveness in delivering therapeutics to striated muscles, which could significantly improve future clinical applications.
View Article and Find Full Text PDF